VNRX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.97 | $985,076 | -$5M |
| 2025 Q4 | -1.05 | $447,034 | -$6M |
| 2025 Q3 | -1.00 | $627,277 | -$3M |
| 2025 Q2 | -1.22 | $406,688 | -$6M |
| 2025 Q1 | -1.12 | $246,385 | -$4M |
| 2024 Q4 | -1.32 | $191,657 | -$6M |
| 2024 Q3 | -1.32 | $474,522 | -$6M |
| 2024 Q2 | -1.69 | $395,797 |
| -$7M |